



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	International Journal of Biochemistry Research & Review
Manuscript Number:	Ms_IJBCRR_20709
Title of the Manuscript:	Effect of Carboplatin and Methotrexate on Lipid Levels in the Plasma Membrane of MCF-7 Cells and their Association with Cell Motility
Type of the Article	Original Research Article

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
Authors have not made any major revisions as suggested. Page numbering is not provided. Reference 2 is from 2007, a recent reference should be used. Cisplatin, carboplatin are not typical alkylating agents. Statement on methotrexate should be revised. Methotrexate inhibits dihydrofolate reductase, a key enzyme for synthesis of tetrahydrofolic acid needed for the thymine, purine and aminoacid synthesis. Since only significant effects on protein levels in plasma membrane are observed; methodology, results and discussion should focus only on this. Other experimental methodology and results should be deleted, may be a sentence or two should be included in discussions. Manuscript should be substantially shortened and could be considered as a brief short note.	Dear Reviewer: thank you again for taking the time to re-check our revised manuscript. Concerning reference 2, it is a book, and this is the latest available edition we have. we have also the biology of cancer by Weinberg but also year 2006. Cisplatin and carboplatin are among the main platinum derived antitumor alkylating drugs used in cancer treatments nowadays. Involvement of the enzyme DHFR in synthesis of some amino acid is added. Lastly, as we were aiming in our project to determine the effect of the two drugs on MCF-7 cell motility which could be effected by lipid level and types in plasma membrane, we prefer to keep the effect of the two drugs on lipid and cell motility.